Epitope First: Immunohistochemistry as a Translational Tool in Drug Development Part 3
From Epitope to Companion Diagnostic:
How Preclinical IHC Informs, But Does Not Define, Clinical Assays
Abstract
Clinical companion diagnostics (CDx) operate under fundamentally different constraints than preclinical assays. While preclinical IHC informs epitope relevance and target biology, clinical assays must deliver reproducible, interpretable results in human tissue. This paper describes how epitope-driven preclinical data are legitimately bridged into clinical assay development through domain class alignment rather than exact epitope identity.
1. The Epitope Does Not Change, the Assay Does
The epitope on a human protein is the same in xenograft tumors and clinical specimens. However, fixation, processing, antibody format, and detection chemistry change how that epitope is accessed and measured.
Thus, preclinical and clinical assays do not measure epitopes identically, even when targeting the same biology.
2. Why Clinical Assays Do Not Require Exact Epitope Matching
Clinical assays prioritize:
- Reproducibility
- Robustness across samples
- Correlation with clinical outcomes
Exact epitope identity is:
- Rarely provable
- Not required for regulatory approval
- Unstable across tissue processing
Instead, clinical assays measure domain class expression in the appropriate cellular compartment.
3. Domain Class as the Translational Bridge
Domain class provides:
- Biological meaning
- Structural stability
- Interpretability across patients
- Regulatory defensibility
A clinical assay that measures expression of the drug-relevant domain class is sufficient to guide patient selection, even if the antibody binds a different epitope within that domain.
4. The Translational Handoff
The correct sequence is:
1. Preclinical IHC demonstrates in vivo availability of the drug-relevant domain.
2. This informs selection of a human-optimized clinical assay.
3. Clinical assay performance is established empirically in human samples.
4. Predictive value is determined through clinical correlation.
Mouse IHC supports the rationale. It does not validate the CDx.
5. Regulatory and Clinical Perspective
Regulators evaluate:
- Assay performance
- Reproducibility
- Clinical correlation
They do not require:
- Epitope sequence identity between preclinical and clinical tools
The translational argument must therefore be biological, not molecularly exact.
Conclusion
Clinical CDx assays are not refined versions of preclinical IHC. They are distinct tools informed by preclinical biology but governed by clinical requirements. Domain class alignment provides the necessary continuity without imposing unrealistic molecular equivalence.
• • •